Stock Analysis

Transgene Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag

Source: Shutterstock

Transgene (EPA:TNG) Full Year 2022 Results

Key Financial Results

  • Revenue: €10.3m (down 39% from FY 2021).
  • Net loss: €32.8m (loss widened by 68% from FY 2021).
  • €0.33 loss per share (further deteriorated from €0.21 loss in FY 2021).
ENXTPA:TNG Earnings and Revenue Growth March 18th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Transgene EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 3.9%.

Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in France.

Performance of the French Biotechs industry.

The company's shares are down 2.7% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for Transgene (of which 1 is a bit concerning!) you should know about.

Valuation is complex, but we're helping make it simple.

Find out whether Transgene is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis